AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33338415
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered via intramuscular injection at baseline, 6 weeks, and then every 3 months for 2 years.
Trial: 33338415
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (1000 mg) administered via intramuscular injection.
Trial: 33338415
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered via intramuscular injection.
Trial: 32147751
Drug: MOP1 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOP1 group received 3 MOPs on the buccal surface of alveolar bone
Trial: 32147751
Drug: MOP2 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOP2 group received 3 buccal MOPs and 3 palatal MOPs
Trial: 32134956
Drug: Naltrexone (NTX)
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naltrexone (NTX) 50 mg daily
Trial: 35381069
Drug: Daily prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily prednisone (0.75 mg/kg)
Trial: 35381069
Drug: Daily deflazacort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily deflazacort (0.90 mg/kg)
Trial: 35381069
Drug: Intermittent prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent prednisone (0.75 mg/kg for 10 days on and then 10 days off)
Trial: 32587591
Drug: PD-1/PD-L1 inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1/PD-L1 inhibitors
Trial: 35493119
Drug: Ibrutinib 420
RxNorm normalized name: ibrutinib 420 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 420 mg plus standard of care (SOC)
Trial: 33159336
Drug: New Forest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New Forest Parenting Programme (NFPP‐SH) + Treatment as Usual (TAU)
Trial: 34636914
Drug: 3A-HBV (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3A-HBV (10 μg)
Trial: 36380220
Drug: Cannabis with
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis with 0 mg CBD (0:1 CBD:THC)
Trial: 36380220
Drug: Cannabis with
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis with 10 mg CBD (1:1 CBD:THC)
Trial: 36380220
Drug: Cannabis with
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis with 20 mg CBD (2:1 CBD:THC)
Trial: 36380220
Drug: Cannabis with
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis with 30 mg CBD (3:1 CBD:THC)
Trial: 32054315
Drug: Pivotal response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pivotal response treatment package
Trial: 35130850
Drug: Sodium hyaluronate
RxNorm normalized name: sodium hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronate (0.1%) combined with rhEGF (20 μg/ml)
Trial: 34393800
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no corticosteroid treatment)
Trial: 36443712
Drug: Dialectical Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behavioral Therapy-based group treatment (DBT-bGT)
Trial: 33930527
Drug: New treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New treatment (hazard ratio equals 0.7)
Trial: 34975830
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (500 mg daily for 14 days)
Trial: 35796695
Drug: Eriomin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eriomin (200 mg/d for 12 weeks)
Trial: 35367955
Drug: Cognitive Therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Therapy with a Well‐Being focus
Trial: 35367955
Drug: Mindfulness Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness Based Cognitive Therapy
Trial: 35029706
Drug: CBD 300
RxNorm normalized name: MENTHOL, UNSPECIFIED FORM 10 g in 100 g / CAMPHOR (SYNTHETIC) 3 g in 100 g TOPICAL CREAM [ETERNAL SPIRIT BEAUTY PAINLESS WITH CBD 3000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD 300 mg
Trial: 39234619
Drug: Antipsychotic medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic medications
Trial: 33629525
Drug: Baerveldt implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baerveldt implant (BGI)
Trial: 34165523
Drug: Reduced-intensity chemotherapy
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-intensity chemotherapy with oxaliplatin and capecitabine
Trial: 34464489
Drug: Locally applied
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Locally applied vaginal estrogen cream
Trial: 32375334
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (70 µg)
Trial: 35696838
Drug: Integrated Exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated Exposure Therapy (I‐PE)
Trial: 35696838
Drug: Integrated Coping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated Coping Skills Therapy (I‐CS)
Trial: 33486855
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg administered immediately after surgery
Trial: 33486855
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg administered 30 min before surgery
Trial: 33486855
Drug: Postoperative analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative analgesic treatment group
Trial: 33486855
Drug: Preoperative analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative analgesic treatment group
Trial: 32144336
Drug: SAP P11-4
RxNorm normalized name: HURA CREPITANS SAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAP P11-4 and twice fluoride varnish
Trial: 32144336
Drug: SAP P11-4
RxNorm normalized name: HURA CREPITANS SAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAP P11-4 and twice weekly SAPM (home-application)
Trial: 33689786
Drug: Estetrol 15
RxNorm normalized name: estetrol
DrugBank: Estetrol (DB12235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Estetrol 15 mg/drospirenone 3 mg (E4/DRSP)
Trial: 33689786
Drug: Ethinylestradiol 20
RxNorm normalized name: Ethinylestradiol 20 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinylestradiol 20 µg/drospirenone 3 mg (EE/DRSP)
Trial: 36076498
Drug: Puerarin supplementation
RxNorm normalized name: Pueraria montana var. chinensis root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Puerarin supplementation (90.2 mg daily)
Trial: 33559524
Drug: VX-210 (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VX-210 (9 mg)
Trial: 33415874
Drug: Jin's three-needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jin's three-needle combined with MyoTrac biostimulation therapy
Trial: 33415874
Drug: simple Jin's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simple Jin's three-needle therapy
Trial: 33415874
Drug: simple MyoTrac
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simple MyoTrac biostimulation therapy
Trial: 34032997
Drug: SARS-CoV-2 antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 antibodies detection using FDA approved ROCHE kit
Trial: 34504990
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy plus ribociclib
Trial: 35691448
Drug: Local consolidative
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local consolidative therapy (LCT) plus standard-of-care systemic therapy or observation
Trial: 33773533
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (counselling, intra oral camera assessment, and carbon monoxide monitoring)
Trial: 33773533
Drug: Counselling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counselling and intra oral camera assessment
Trial: 36133438
Drug: Periocline-assisted periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periocline-assisted periodontal basic therapy
Trial: 36133438
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (periodontal basic therapy without periocline)
Trial: 33060258
Drug: Aerosolized calfactant
RxNorm normalized name: Calfactant
DrugBank: Calfactant (DB06415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosolized calfactant (Infasurf), 6 mL/kg (210 mg phospholipid/kg body weight), up to 3 treatments, at least 4 hours apart.
Trial: 33681685
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy
Trial: 33401223
Drug: Aspirin (AP)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (AP)
Trial: 33401223
Drug: Combination (A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination (A + S)
Trial: 33692185
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser (LLL, AsGaAl) at a wavelength of 780 nm (Laser XT Therapy, DMC, São Carlos, Brazil)
Trial: 36046939
Drug: Medical nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical nutrition therapy (MNT)
Trial: 35387739
Drug: Single-dose antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose antibiotic prophylaxis (2 g amoxicillin 1 h before surgery)
Trial: 35387739
Drug: Single-dose prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose prophylactic antibiotic (2 g amoxicillin 1 h before surgery) with additional doses after surgery (500 mg amoxicillin, q8h for 5 days)
Trial: 35387739
Drug: Post-surgical antibiotics
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-surgical antibiotics alone (500 mg amoxicillin, q8h for 5 days)
Trial: 33767791
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg body weight)
Trial: 33767791
Drug: Nesdonal (3-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nesdonal (3-5 mg/kg body weight)
Trial: 616118926
Drug: 20 mm
RxNorm normalized name: Adapta-Cap B 20 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mm diameter implant
Trial: 35098466
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg Cd/kg of feed
Trial: 35098466
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg Cd/kg of feed
Trial: 35098466
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg Cd/kg of feed
Trial: 35555782
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D and calcium supplementation (2000 IU/d vitamin D3 and 1500 mg/d calcium)
Trial: 39632341
Drug: LEM 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEM 10 mg
Trial: 35748777
Drug: LEM 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEM 20 mg
Trial: 35748777
Drug: LEM 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEM 30 mg
Trial: 35749758
Drug: Zolpidem (ZOL)
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zolpidem (ZOL) 30 mg
Trial: 35749758
Drug: Suvoxexant (SUV)
RxNorm normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suvoxexant (SUV) 40 mg
Trial: 32967921
Drug: Metformin (DM+MF)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (DM+MF)
Trial: 38770009
Drug: Mepolizumab 100
RxNorm normalized name: mepolizumab 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab 100 mg subcutaneously every 4 weeks for 52 weeks
Trial: 35822924
Drug: Mepolizumab 100
RxNorm normalized name: mepolizumab 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab 100 mg subcutaneously
Trial: 34455849
Drug: Abbreviated antiplatelet
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abbreviated antiplatelet therapy (APT) for 5 months in patients with OAC indication; 11 months in patients without OAC indication.
Trial: 36002048
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of NL003
Trial: 35507141
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline plus oral acetazolamide (5 mg/kg/day)
Trial: 35507141
Drug: Half saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half saline plus 75 mEq/L sodium bicarbonate
Trial: 34193503
Drug: Daily PEP
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily PEP flute usage as add-on to usual care
Trial: 33407760
Drug: Regression approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regression approach for personalised treatment recommendation
Trial: 34313633
Drug: Enhanced vasodilation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced vasodilation treatment (EVT) based on renin‐angiotensin blockade and/or amlodipine
Trial: 34313633
Drug: Reduced vasodilation
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced vasodilation treatment (RVT) based on nonvasodilating β‐blockade (metoprolol)
Trial: 33657403
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with rivaroxaban and an antiplatelet agent
Trial: 32293463
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal therapy (HFNT) during pulmonary rehabilitation (PR)
Trial: 32293463
Drug: Non-high-flow nasal
RxNorm normalized name: marine non-gelling gelatin, high MW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-high-flow nasal therapy (non-HFNT) during pulmonary rehabilitation (PR)
Trial: 34906660
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) delivered via mobile phone messaging for 14 days, twice daily messages
Trial: 33338430
Drug: Multisensory-motor training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisensory-motor training to distinguish mirror letters (e.g., 'b' vs 'd') for 7.5 hours combined with post-training sleep.
Trial: 33047586
Drug: Routine mesoappendixectomy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine mesoappendixectomy, restrictive strategy for abdominal drainage, and postoperative antibiotic prevention (main group)
Trial: 32845021
Drug: Multinutrient supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multinutrient supplements (fish oil and multivitamin)
Trial: 32845021
Drug: Multinutrient supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multinutrient supplements and food‐related behavioral activation therapy (F‐BA)
Trial: 32845021
Drug: Placebos and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos and food‐related behavioral activation therapy (F‐BA)
Trial: 36410405
Drug: Canine-assisted intervention
RxNorm normalized name: CanineAid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canine-assisted intervention (CAI) consisting of 35-min weekly sessions over 6 weeks
Trial: 34378511
Drug: Saline (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (no treatment)
Trial: 32660566
Drug: Long-term (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-term (6 days) supplementation of amaranth concentrate derived dietary NO3- (±400 mg)
Trial: 33089386
Drug: Lactic acid
RxNorm normalized name: Lactic Acid
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactic acid 30% with ferulic peel 12% (combination peel)
Trial: 33089386
Drug: Ferulic peel
RxNorm normalized name: orange peel extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferulic peel 12% alone (monotherapy)
Trial: 32098219
Drug: Acute EGCG
RxNorm normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute EGCG administration (morning and evening in mice)
Trial: 36200646
Drug: High‐dose dual‐impregnated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High‐dose dual‐impregnated antibiotic‐loaded cement (DIAC) including gentamicin and clindamycin
Trial: 36200646
Drug: Low‐dose single‐impregnated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low‐dose single‐impregnated gentamicin antibiotic‐loaded cement (SIAC)
Trial: 32536106
Drug: Nonsplint group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsplint group (oral information about daily activities)
Trial: 33675139
Drug: Statistical methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statistical methods for estimating treatment effects
Trial: 33066334
Drug: Combined nutraceutical
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined nutraceutical containing phytosterols (800 mg) and red yeast rice (5 mg of monacolins), niacin (27 mg), and policosanols (10 mg)
Trial: 35554955
Drug: Oral eltrombopag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral eltrombopag (50 mg daily)
Trial: 35554955
Drug: Subcutaneous rhTPO
RxNorm normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous rhTPO (15000U daily)
Trial: 35970302
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SOC; salvage chemoimmunotherapy followed by high-dose therapy with autologous stem cell rescue for responders)
Trial: 33279374
Drug: Oral olanzapine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral olanzapine, risperidone, amisulpride, aripiprazole, or perphenazine (Phase 1)
Trial: 33279374
Drug: Oral olanzapine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral olanzapine, amisulpride, or clozapine (Phase 2)
Trial: 33279374
Drug: Clozapine extended
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine extended treatment or modified electroconvulsive therapy (Phase 3A)
Trial: 35640246
Drug: Postoperative mFOLFOX6
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative mFOLFOX6 (12 courses of intravenous oxaliplatin [85 mg/m2] with L-leucovorin [200 mg/m2] followed by 5-fluorouracil [400 mg/m2, bolus and 2400 mg/m2, continuous infusion, repeated every 2 weeks])
Trial: 33784467
Drug: VAULT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAULT treatment with brief utterances (four words or fewer)
Trial: 33784467
Drug: VAULT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAULT treatment with extended utterances (five words or more)
Trial: 33784467
Drug: CART analysis
RxNorm normalized name: prilocaine
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CART analysis for treatment responders
Trial: 33764102
Drug: Intranasal amphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal amphetamine administration
Trial: 33589758
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure treatment (systolic BP target of 120 mm Hg)
Trial: 33589758
Drug: Standard blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard blood pressure treatment (systolic BP target of 140 mm Hg)
Trial: 34301646
Drug: Dexamethasone alongside
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone alongside standard antiviral treatment with aciclovir
Trial: 34265791
Drug: Methadone (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (2.5 mg/12 h) in combination with morphine
Trial: 32331082
Drug: Lurasidone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone (40 mg/day or 80 mg/day)
Trial: 33559971
Drug: Eurycoma longifolia
RxNorm normalized name: Eurycoma longifolia root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eurycoma longifolia 600 mg/day for two weeks
Trial: 35661898
Drug: Targeted home
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted home visits by community nurses post treatment administration